Online citations, reference lists, and bibliographies.
← Back to Search

Bcr-Abl Variants: Biological And Clinical Aspects.

A. Advani, A. Pendergast
Published 2002 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Bcr-Abl is an oncogene that arises from fusion of the Bcr gene with the c-Abl proto-oncogene. Three different Bcr-Abl variants can be formed, depending on the amount of Bcr gene included: p185, p210, and p230. The three variants are associated with distinct types of human leukemias. Examination of the signaling pathways differentially regulated by the Bcr-Abl proteins will help us gain better insight into Bcr-Abl mediated leukemogenesis.
This paper references
10.1016/S1074-7613(00)80452-5
Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.
D. Afar (1997)
Molecular analysis of Philadelphia positive essential thrombocythemia.
P. Martiat (1989)
10.1111/j.1365-2141.1988.tb02426.x
Cytogenetic studies of haemopoietic colonies from patients with an initial diagnosis of acute lymphoblastic leukaemia
D. Kalousek (1988)
10.1073/PNAS.210253497
BCR/ABL inhibition by an escort/phosphatase fusion protein.
Y. M. Lim (2000)
10.1006/GENO.1995.1008
Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation.
S. Chissoe (1995)
10.1016/S0092-8674(00)81840-1
p62dok: A Constitutively Tyrosine-Phosphorylated, GAP-Associated Protein in Chronic Myelogenous Leukemia Progenitor Cells
N. Carpino (1997)
10.1093/jnci/89.21.1616
Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
A. Delannoy (1997)
10.1097/00001622-199603000-00004
Donor lymphocyte infusions
S. Giralt (1996)
10.1111/j.1365-2141.1995.tb05236.x
OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA
A. Spencer (1995)
10.1111/j.1365-2141.1988.tb02428.x
Difference of cell lineage expression of haematopoietic progenitor cells in Philadelphia‐positive acute lymphoblastic leukaemia and chronic myelogenous leukaemia
K. Kitano (1988)
10.1073/PNAS.84.18.6558
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
J. Mclaughlin (1987)
10.1172/JCI115234
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
H. Ahuja (1991)
10.1074/jbc.271.49.31704
P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members*
R. Ilaria (1996)
10.1200/JCO.1992.10.3.398
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
H. Kantarjian (1992)
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line.
T. Oda (1995)
10.1073/PNAS.88.14.6293
p53 in chronic myelogenous leukemia in acute phase.
E. Feinstein (1991)
10.1084/JEM.189.9.1399
The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity
Shaoguang Li (1999)
10.1038/sj.onc.1201400
The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells
D. Cortez (1997)
Differences in tyrosine phosphorylated proteins between cells expressing P210bcr/abl and P190bcr/abl.
J. Nishimura (1992)
10.1016/S0002-9343(96)00061-7
Chronic myelogenous leukemia: a review.
J. Cortes (1996)
Chronic myelogenous leukemia: update on biology and treatment.
S. Faderl (1999)
10.1128/MCB.11.10.5016
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.
J. O’Bryan (1991)
10.1101/GAD.12.7.968
A requirement for NF-κB activation in Bcr–Abl-mediated transformation
J. Y. Reuther (1998)
10.1182/BLOOD.V95.11.3498.011K27_3498_3505
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
E. Weisberg (2000)
10.1002/1097-0142(19880815)62:4<672::AID-CNCR2820620404>3.0.CO;2-T
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high‐dose cytosine arabinoside
H. Kantarjian (1988)
10.1200/JCO.1988.6.1.180
Definition of the accelerated phase of chronic myelogenous leukemia.
H. Kantarjian (1988)
10.1182/BLOOD.V97.5.1404
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
D. G. Peters (2001)
Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location.
S. Elliott (1995)
10.1182/BLOOD.V97.1.4
The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
S. Roumiantsev (2001)
10.1182/BLOOD.V85.9.2632.BLOODJOURNAL8592632
Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
J. Radich (1995)
First intron and M-bcr breakpoints are restricted to the lymphoid lineage in Philadelphia positive acute lymphoblastic leukemia.
J. M. Craig (1990)
10.1182/BLOOD.V88.7.2375.BLOODJOURNAL8872375
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
J. Melo (1996)
10.1097/00062752-199704040-00009
Chronic myeloid leukemia
J. Goldman (1997)
10.1093/emboj/16.20.6151
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway
T. Skorski (1997)
10.1056/NEJM200104053441409
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
J. Goldman (2001)
Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
T. Lion (1995)
10.1016/0165-4608(85)90039-1
The significance of cytogenetic findings of erythroid colonies derived from a Ph+ ALL patient: fundamental differences between Ph+ ALL and blastic phase CML.
R. Abe (1985)
10.1126/SCIENCE.6587568
Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.
S. Collins (1984)
10.1073/PNAS.92.22.10282
Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family.
T. Chuang (1995)
10.1038/243290A0
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining
J. Rowley (1973)
10.1054/BLRE.1999.0119
Biology of BCR-ABL.
R. Chopra (1999)
10.1056/NEJM199907153410306
The biology of chronic myeloid leukemia.
S. Faderl (1999)
10.1182/BLOOD.V86.6.2371.BLOODJOURNAL8662371
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
A. Gaiger (1995)
10.1182/BLOOD.V73.5.1291.BLOODJOURNAL7351291
Comparative biochemical and cytogenetic studies of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and other 22q 11 variants
L. Dow (1989)
10.1038/nm0596-561
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
B. Druker (1996)
10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C
Characteristics of accelerated disease in chronic myelogenous leukemia
H. Kantarjian (1988)
10.1038/sj.onc.1201490
BCR – ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
N. Cambier (1998)
10.1002/1097-0142(19940301)73:5<1526::AID-CNCR2820730534>3.0.CO;2-E
Lineage switch in Philadelphia chromosome‐ positive acute lymphoblastic leukemia
David A. Reardon (1994)
10.1126/SCIENCE.2406902
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
G. Q. Daley (1990)
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
E. Buchdunger (1996)
rac, a novel ras-related family of proteins that are botulinum toxin substrates.
J. Didsbury (1989)
10.1126/SCIENCE.2408149
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
T. G. Lugo (1990)
10.1182/BLOOD.V96.3.1070.015K17_1070_1079
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
F. X. Mahon (2000)
10.1182/BLOOD.V88.7.2410.BLOODJOURNAL8872410
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
F. Pane (1996)
10.1073/PNAS.92.25.11746
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
A. B. Raitano (1995)
10.1038/325635A0
A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia
L. C. Chan (1987)
10.1182/BLOOD.V72.2.784.BLOODJOURNAL722784
Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia
L. Secker-Walker (1988)
10.3109/10428199309047856
The cytogenetic scenario of chronic myeloid leukemia.
F. Mitelman (1993)
10.1128/MCB.15.10.5531
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
D. Cortez (1995)
10.1182/BLOOD.V82.3.1035B.BLOODJOURNAL8231035B
Clonal nature of chronic neutrophilic leukemia [letter] [see comments]
Y. Kwong (1993)
10.1097/00001622-199401000-00004
Chronic myelogenous leukemia.
M. Mauro (1994)
10.1016/S0950-3536(05)80204-5
5 Therapy and prognostic factors in adult acute lymphoblastic leukaemia
D. Hoelzer (1994)
10.1016/S0959-437X(05)80338-7
Abl tyrosine kinase in signal transduction and cell-cycle regulation.
J. Wang (1993)
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Z. Estrov (1993)
10.1084/JEM.187.12.1995
Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant
P. Salomoni (1998)
10.1038/sj.onc.1201342
Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein
John R McWhirter (1997)
10.1038/sj.leu.2401321
BCR/ABL rearrangement and leukemia phenotype
G. Saglio (1999)
10.1056/NEJM199904293401706
Chronic myeloid leukemia.
C. Sawyers (1999)
Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and terminating into megakaryoblastic blast crisis: report of two cases with molecular studies.
F. Cervantes (1993)
10.1097/00000441-192007000-00003
A CASE OF SPLENOMEGALY WITH POLYMORPHONUCLEAR NEUTROPHIL HYPERLEUKOCYTOSIS
E. L. Tuohy (1920)
Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia.
T. Fioretos (1993)
10.1073/PNAS.190104497
Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity.
Y. Jiang (2000)
10.3109/10428199509059612
BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.
T. Cotter (1995)
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
J. Melo (1994)
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.
K. Okuda (1994)
10.1182/BLOOD.V95.9.2913.009K32_2913_2921
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
R. C. Quackenbush (2000)
10.1093/emboj/16.1.121
Mouse disabled (mDab1): a Src binding protein implicated in neuronal development
B. Howell (1997)
10.1182/BLOOD.V83.5.1179.BLOODJOURNAL8351179
BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death
A. J. McGahon (1994)
10.1182/BLOOD.V87.12.5213.BLOODJOURNAL87125213
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
F. van Rhee (1996)
Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia.
C. Rozman (1995)
10.1016/S0301-472X(01)00633-6
Novel therapies for chronic myelogenous leukemia.
B. Jahagirdar (2001)
10.1016/S0065-230X(08)60423-6
Chromosome abnormalities in malignant hematologic diseases.
J. Rowley (1982)
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
C. A. Evans (1993)
10.1016/0165-4608(92)90086-N
Inversion of chromosome 16 and bone marrow eosinophilia in a myelomonocytic transformation of chronic myeloid leukemia.
N. Asou (1992)
10.1016/S0304-419X(97)00023-1
Signal transduction by wild-type and leukemogenic Abl proteins.
A. B. Raitano (1997)
10.1074/jbc.273.48.32360
Interactions of p62 dok with p210 bcr-abl and Bcr-Abl-associated Proteins*
A. Bhat (1998)
10.1126/SCIENCE.277.5326.693
A cytoplasmic inhibitor of the JNK signal transduction pathway.
M Dickens (1997)
10.1016/0145-2126(94)90023-X
Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis.
G. Nanjangud (1994)
10.1038/sj.leu.2401467
Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays
S Ghaffari (1999)
10.1038/sj.leu.2401565
Chronic myeloid leukemia from basics to bedside
S. Thijsen (1999)
10.1126/SCIENCE.1375394
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro.
M. Gishizky (1992)
10.1182/BLOOD.V87.3.1075.BLOODJOURNAL8731075
Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis.
G. Saglio (1996)
10.1073/PNAS.92.21.9540
Signaling by ABL oncogenes through cyclin D1.
D. Afar (1995)
10.1016/0002-9343(87)90754-6
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
H. Kantarjian (1987)
10.1182/BLOOD.V78.12.3125.3125
A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia [see comments]
K. Inokuchi (1991)
10.1182/BLOOD.V96.6.2226.H8002226_2226_2232
Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
N. Heisterkamp (2000)
10.1101/GAD.12.10.1415
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway.
Z. Dai (1998)
10.1016/S0092-8674(00)81841-3
Identification of the Abl- and rasGAP-Associated 62 kDa Protein as a Docking Protein, Dok
Y. Yamanashi (1997)
10.1182/BLOOD.V74.8.2629.BLOODJOURNAL7482629
Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia
Pc Cogswell (1989)
10.3109/10428190009148847
Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia
S. Faderl (2000)
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
K. Shuai (1996)
10.1016/0002-9343(93)90122-6
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
P. M. Derderian (1993)
10.3109/10428199809057542
Changes in oncogene expression implicated in evolution of chronic granulocytic leukemia from its chronic phase to acceleration.
Z. Beck (1998)
10.1074/jbc.272.26.16170
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells*
A. Bhat (1997)
10.1016/S0065-230X(08)60998-7
Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia.
G. Q. Daley (1991)
10.1111/j.1365-2141.1995.tb08362.x
Analysis of molecular breakpoint and m‐RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival
P. Shepherd (1995)
10.1182/BLOOD.V97.1.277
The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
X. Zhang (2001)
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
K. Okuda (1996)
10.1016/S0092-8674(05)80094-7
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
A. Pendergast (1993)
10.1126/SCIENCE.289.5486.1938
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
T. Schindler (2000)
10.1182/blood.v78.4.1078.bloodjournal7841078
Entire ABL gene is joined with 5'-BCR in some patients with Philadelphia-positive leukemia.
C. Morris (1991)
Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene.
K. Mills (1991)
10.3109/10428199309047862
The role of myc in transformation by BCR-ABL.
C. Sawyers (1993)
10.1007/978-3-642-61122-3_18
Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.
D. Afar (1994)
10.1126/SCIENCE.8153630
Differential complementation of Bcr-Abl point mutants with c-Myc.
D. Afar (1994)
10.1016/0092-8674(91)90148-R
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
A. Pendergast (1991)
10.1016/0092-8674(92)90241-4
Dominant negative MYC blocks transformation by ABL oncogenes
C. Sawyers (1992)
10.1182/BLOOD.V78.9.2178.BLOODJOURNAL7892178
Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia.
M. Towatari (1991)
10.1182/BLOOD.V61.1.85.BLOODJOURNAL61185
Differentiation patterns in the blastic phase of chronic myeloid leukemia.
J. Griffin (1983)
10.1016/S0950-3536(11)80051-X
Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products.
P. Allen (1992)
10.1126/SCIENCE.1062538
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
M. E. Gorre (2001)
10.1200/JCO.1988.6.1.18
Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas.
T. Kinsella (1988)
10.3109/10428199309064268
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
C. Sawyers (1993)
10.1182/BLOOD.V82.3.691.BLOODJOURNAL823691
Chronic myelogenous leukemia: a concise update.
H. Kantarjian (1993)
10.1084/JEM.181.1.307
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
C. Sawyers (1995)
10.1016/0092-8674(92)90163-7
The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors
A. Ridley (1992)
10.1182/BLOOD.V78.9.2411.BLOODJOURNAL7892411
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
H. Kantarjian (1991)
10.1038/325631A0
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
R. Kurzrock (1987)
10.1182/BLOOD.V92.7.2450.2450_2450_2460
Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
G. Burgess (1998)
10.1074/jbc.272.51.32649
BCR/ABL-induced Leukemogenesis Causes Phosphorylation of Hef1 and Its Association with Crkl*
R. de Jong (1997)
10.1074/jbc.274.35.24980
Tyrosine Phosphorylation of Tub and Its Association with Src Homology 2 Domain-containing Proteins Implicate Tub in Intracellular Signaling by Insulin*
R. Kapeller (1999)
10.1182/BLOOD.V86.2.726.BLOODJOURNAL862726
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
T. Skorski (1995)
10.1128/MCB.9.5.1866
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
J. Mclaughlin (1989)
10.1016/S0950-3536(97)80003-0
BCR-ABL gene variants.
J. Melo (1997)
Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT).
A. Gratwohl (1996)
10.1002/AJH.2830430416
Successful alpha‐2b‐interferon therapy for chronic neutrophilic leukemia
S. Meyer (1993)
10.1073/PNAS.85.6.1952
Transforming genes in chronic myelogenous leukemia.
E. Liu (1988)



This paper is referenced by
10.1186/s12943-018-0788-y
Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
K. S. Siveen (2018)
10.1038/sj.pcan.4500697
Molecular biology of prostate cancer
M. Karayi (2004)
10.1016/j.bjhh.2014.07.016
Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
Ilana de França Azevedo (2014)
10.1016/j.colsurfb.2016.09.029
Attomolar electrochemical detection of the BCR/ABL fusion gene based on an amplifying self-signal metal nanoparticle-conducting polymer hybrid composite.
Karen Yasmim Pereira dos Santos Avelino (2016)
Abstract. Smad4 is a critical regulator of transforming growth factor (TGF)-β signaling and is defective in numerous human cancers. In total, 30% of pancreatic cancers harbor a homozy-
Onica Legendre (2014)
10.1038/sj.bjc.6603054
Net1 and Myeov: computationally identified mediators of gastric cancer
J. Leyden (2006)
10.1038/onc.2012.284
Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo
H. Gil-Henn (2013)
THE ROLE OF MED 12 IN TUMORIGENESIS
K. Kämpjärvi (2016)
10.1016/S1521-6926(03)00072-0
Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia.
F. Lococo (2003)
10.1016/J.TCB.2003.11.003
How do Abl family kinases regulate cell shape and movement?
S. E. Hernández (2004)
The mechanism of CD24-mediated apoptosis in bone marrow-derived early B-cells.
D. Ayre (2014)
10.1007/s13277-014-1701-y
Resveratrol induces human K562 cell apoptosis, erythroid differentiation, and autophagy
Hui-Wen Yan (2014)
10.1038/sj.bjc.6604688
NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer
D. Murray (2008)
10.1007/978-3-319-62146-3_5
Chronic Myeloid Leukemia, BCR-ABL1 Positive
R. Wang (2018)
10.1016/S0006-2952(03)00501-X
Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition.
A. Duvoix (2003)
Ph-positive leukemias in the era of modern cytogenetics, molecular biology, tyrosine kinase inhibitors and hematopoietic stem cell transplantation
Nikolay Mamaev (2010)
10.1201/B19000-6
Pharmacogenomics and Laboratory Medicine
Jianbo Song (2016)
10.1038/nature01608
Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia
H. Jumaa (2003)
10.1007/978-1-59259-791-8_12
Molecular Diagnostics in Neoplastic Hematopathology
D. Arber (2004)
The role of PI3K in Ephrin-A1 induced cell retraction
Daniel James Fero (2008)
10.18632/ONCOTARGET.2439
The structural basis for cancer treatment decisions
R. Nussinov (2014)
Role of the drug transporters in the multidrug resistance affecting bosutinib treatment
P. Perini (2011)
10.1007/978-0-387-69132-9
Mouse Models of Human Blood Cancers
S. Li (2008)
10.1007/978-1-59259-431-3_8
Molecular Pathology of Hematological Malignancies
A. Killeen (2004)
10.1016/J.LEUKRES.2003.10.027
Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature.
Y. Keung (2004)
10.1096/fj.03-0322
Imatinib induces mitochondria‐dependent apoptosis of the Bcr‐Abl‐positive K562 cell line and its differentiation toward the erythroid lineage 1
A. Jacquel (2003)
Regulation of the Apoptosome in Cancer
Jiyeon Kim (2012)
10.1007/978-0-387-69132-9_7
Modeling Human Philadelphia Chromosome-Positive Leukemia in Mice
S. Li (2008)
Investigating allosteric regulation of ABL and BCR-ABL kinases: Implications for small molecule inhibitors
Shoghag B. Panjarian (2012)
10.1038/sj.leu.2404787
Identification of T-cell epitopes for cancer immunotherapy
J. H. Kessler (2007)
10.1007/978-1-59259-791-8
Cancer Diagnostics
J. Wu (2004)
10.1091/MBC.E07-01-0008
Using Bcr-Abl to examine mechanisms by which abl kinase regulates morphogenesis in Drosophila.
Traci Stevens (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar